SPOTLIGHT: GPC finds positive satraplatin data


Researchers at GPC Biotech say that they've discovered that a group of patients previously treated with Taxotere demonstrated a positive trend toward survival when treated with the experimental prostate cancer drug satraplatin. That data has persuaded the company to continue research on the therapy, which failed a pivotal late-stage trial. Report